MODA is now a Lonza company
Walkersville, MD (PRWEB) July 6, 2010 -- Lonza Group Ltd will offer a live, interactive Webinar to discuss its successful move to paperless environmental monitoring (EM) using the MODA™ solution and its acquisition of MODA Technology Partners on Tuesday, July 20, 2010. The Webinar will offer two optional times: 8:00 AM EST (International) and 11:00 AM EST (US).
The presentation will feature Douglas Danne, Head of Rapid Testing Solutions at Lonza Bioscience and Susan Harrison, Senior Manager of Microbiology at Lonza Walkersville.
This Webinar will share Lonza's success, its vision on quality systems automation, and its thoughts on how the integration of the MODA™ product line into Lonza's offerings provides a positive impact on the life sciences industry.
Webinar topics will include:
Life-science industry leader Lonza moves to paperless EM
Lonza Bioscience's Walkersville, Maryland facility operates 13 clean room suites, with the majority of these suites supporting Class 100/ISO 5 Aseptic Processing operations, requiring an extensive EM program that generates large volumes of data.
In 2007, Lonza Walkersville chose to automate the EM program using mobile, wireless and informatics technologies by MODA™ - a paperless QC micro solution. The effort was a part of a company-wide Lean Six Sigma (LSS) initiative to eliminate waste, reduce lead and labor time, and improve overall compliance.
Acquisition of MODA benefits Lonza and its customers
The MODA™ solution quickly proved successful, giving Lonza the confidence to initiate a global deployment across all of its manufacturing plants. In May 2010, Lonza acquired MODA Technology Partners and added the MODA™ product line as a key component to its informatics platform offered by the Rapid Testing Solutions business unit.
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.
Read the full story at http://www.prweb.com/releases/2010/07/prweb4220514.htm.
Copyright©2010 Vocus, Inc.
All rights reserved